Last reviewed · How we verify
Mycobacterium Vaccae for Injection
Mycobacterium Vaccae for Injection is a Immunotherapeutic vaccine Biologic drug developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. It is currently FDA-approved for Tuberculosis (adjunctive immunotherapy in combination with standard anti-TB chemotherapy), Mycobacterial infections.
Mycobacterium vaccae is an inactivated whole-cell vaccine that stimulates the immune system to enhance Th1-mediated cellular immunity against tuberculosis and other mycobacterial infections.
Mycobacterium vaccae is an inactivated whole-cell vaccine that stimulates immune responses to enhance anti-tuberculosis immunity and potentially modulate Th1/Th2 balance. Used for Tuberculosis (adjunctive immunotherapy in combination with standard anti-TB chemotherapy), Pulmonary tuberculosis.
At a glance
| Generic name | Mycobacterium Vaccae for Injection |
|---|---|
| Sponsor | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| Drug class | Immunotherapeutic vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains heat-inactivated Mycobacterium vaccae, a non-pathogenic mycobacterium that primes dendritic cells and T cells to shift the immune response toward a Th1 phenotype, enhancing cell-mediated immunity. This approach is designed to boost protective immune responses in patients with tuberculosis or to provide adjunctive immunotherapy in combination with standard anti-TB drugs. The mechanism relies on pattern recognition receptors and mycobacterial antigens to activate innate and adaptive immunity.
Approved indications
- Tuberculosis (adjunctive immunotherapy in combination with standard anti-TB chemotherapy)
- Mycobacterial infections
Common side effects
- Local injection site reactions (erythema, induration, pain)
- Fever
- Fatigue
- Headache
Key clinical trials
- Clinical Trial of Mica (PHASE4)
- Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycobacterium Vaccae for Injection CI brief — competitive landscape report
- Mycobacterium Vaccae for Injection updates RSS · CI watch RSS
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. portfolio CI
Frequently asked questions about Mycobacterium Vaccae for Injection
What is Mycobacterium Vaccae for Injection?
How does Mycobacterium Vaccae for Injection work?
What is Mycobacterium Vaccae for Injection used for?
Who makes Mycobacterium Vaccae for Injection?
What drug class is Mycobacterium Vaccae for Injection in?
What development phase is Mycobacterium Vaccae for Injection in?
What are the side effects of Mycobacterium Vaccae for Injection?
Related
- Drug class: All Immunotherapeutic vaccine drugs
- Manufacturer: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Tuberculosis (adjunctive immunotherapy in combination with standard anti-TB chemotherapy)
- Indication: Drugs for Mycobacterial infections
- Compare: Mycobacterium Vaccae for Injection vs similar drugs
- Pricing: Mycobacterium Vaccae for Injection cost, discount & access